On June 2, 2026, the FDA’s Center for Biologics Evaluation and Research released a draft guidance titled Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing.
Gene therapy is one of the most promising avenues for CMT precisely because it addresses the underlying genetic cause rather than managing symptoms. CMTRF has funded multiple gene therapy programs, and the developers behind those programs face the same regulatory requirements as programs targeting far more common diseases, often with far fewer resources to meet them.
At CMTRF, we have been watching the gene therapy regulatory landscape closely for years, and this guidance is worth examining carefully.
Our read: there is genuine reason for optimism, alongside a few open questions as the guidance moves toward finalization.
What the guidance says
At its core, the guidance formalizes a framework that allows developers to carry forward knowledge from one gene therapy program into the next, rather than starting from scratch each time.
What can be leveraged under the new framework:
- Manufacturing and analytical methods. Validated assay platforms, lot release specifications, and process characterization data can be shared across products using similar manufacturing processes, reducing duplicative validation work.
- Nonclinical data. Proof-of-concept data from pre-clinical models, biodistribution studies, and toxicology findings can be applied to subsequent programs where the editor, delivery vector, and formulation are sufficiently similar.
- Bioinformatics pipelines. Off-target analysis strategies, next-generation sequencing methods, and analysis pipelines can be shared across programs using identical editing mechanisms, with product-specific parameters updated as needed.
- Clinical experience. Safety databases, pharmacokinetic data, dose-selection rationale, and monitoring protocols from prior trials can inform the design and conduct of new trials for related products.
The guidance is careful to frame all of this as recommendations rather than requirements, and it emphasizes that sponsors must provide rigorous scientific justification for any leveraging proposal.
Why this matters for CMT
Charcot-Marie-Tooth disease presents a uniquely demanding development landscape. With more than 140 genes implicated across its many subtypes, CMT is in some ways not a single disease but a family of diseases that share a clinical presentation. Each genetic subtype, in principle, may require its own therapeutic approach. That reality has long been both a challenge and a driver of scientific innovation in the CMT space.
The ability to carry manufacturing knowledge, validated assay platforms, nonclinical safety data, and clinical learnings from one subtype program into another could be genuinely transformative for this field.
If a developer demonstrates safety and biodistribution for a gene therapy targeting one CMT subtype, and a second program uses the same delivery vector, the same manufacturing platform, and targets a related genetic mechanism, the new framework could allow meaningful data sharing between those programs. That compresses timelines and reduces costs at exactly the point in development where rare disease programs are most vulnerable to stalling.
“We look forward to learning more about how this guidance would be implemented, as gene therapies like the ones we’ve supported through the research cycle offer some of the most promising treatments in the CMT space and in rare disease broadly. Enabling developers to carry hard-won manufacturing and clinical knowledge from one program into the next breaks down one of the biggest barriers standing between patients and treatment, and for a disease with as many genetic subtypes as CMT, that kind of regulatory efficiency will be transformative.”
Meghan Drummond, VP of Research & Drug Development, CMTRF
Where we see open questions
The framework places significant weight on the degree of similarity between products and platforms. For CMT gene therapy programs, which may share a delivery mechanism but target distinct genomic loci across subtypes, it will be important to understand where the FDA draws the line on “sufficient similarity.”
The guidance acknowledges that off-target data, on-target editing outcomes, and genomic integrity assessments are generally not appropriate for direct transfer between programs targeting different sites, even when the editing mechanism is identical. That limits some of the potential efficiency gains for a disease as genetically heterogeneous as CMT.
CMTRF exists to accelerate the path from research to treatment for the CMT community, and we look forward to seeing what opportunities this guidance, if finalized, can create.
